Psychiatry Research: Neuroimaging
Volume 154, Issue 1 , Pages 85-92 , 15 January 2007

Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive–compulsive disorder patients

  • Satsuki Sumitani

      Affiliations

    • Department of Psychiatry, Institute of Health Biosciences, University of Tokushima Graduate School, 18-15 Kuramoto-cho 3, Tokushima 770-8503, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 88 633 7130; fax: +81 88 633 7131.
    • ,
  • Masafumi Harada

      Affiliations

    • Department of Radiologic Technology, School of Health Sciences, University of Tokushima, Tokushima, Japan
    • ,
  • Hitoshi Kubo

      Affiliations

    • Department of Radiologic Technology, School of Health Sciences, University of Tokushima, Tokushima, Japan
    • ,
  • Tetsuro Ohmori

      Affiliations

    • Department of Psychiatry, Institute of Health Biosciences, University of Tokushima Graduate School, 18-15 Kuramoto-cho 3, Tokushima 770-8503, Japan

Received 29 August 2005 ,Revised 30 January 2006 ,Accepted 13 February 2006.

References 

  1. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive–compulsive disorder. Journal of Clinical Psychopharmacology. 1998;18:185–192
  2. Ackerman DL, Greenland S, Bystritsky A. Side effects as predictor of drug response in obsessive–compulsive disorder. Journal of Clinical Psychopharmacology. 1999;19:459–465
  3. Baker PB. N-acetyl aspartate—a neuronal marker?. Annals of Neurology. 2001;49:423–424
  4. Bartha R, Stein MB, Williamson PC, Drost DJ, Neufeld RW, Carr TJ, et al. A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive–compulsive disorder and comparison subjects. American Journal of Psychiatry. 1998;155:1584–1591
  5. Baslow MH. Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system: an analytical review. Neurochemistry International. 2002;40:295–300
  6. Baslow MH. N-acetyl aspartate in the vertebrate brain: metabolism and function. Neurochemistry Research. 2003;28:941–953
  7. Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive–compulsive disorder—a comparison with rates in unipolar depression and in normal controls. Archives of General Psychiatry. 1987;44:211–218
  8. Baxter LR, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, et al. Cerebral glucose metabolic rates in non-depressed obsessive–compulsives. American Journal of Psychiatry. 1988;145:1560–1563
  9. Baxter LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive–compulsive disorder. Archives of General Psychiatry. 1992;49:681–689
  10. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry. 1998;43:641–648
  11. Breiter HC, Rauch SL, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN, et al. Functional magnetic resonance imaging of symptom provocation in obsessive–compulsive disorder. Archives of General Psychiatry. 1996;49:595–601
  12. Bustillo J, Wolff C, Myers-y-Gutierrez A, Dettmer TS, Cooper TB, Allan A, et al. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophrenia Research. 2004;66:31–39
  13. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive–compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry. 2004;65:565–568
  14. Crespo-Facorro B, Cabranes JA, Lopez-Ibor Alcocer MI, Paya B, Perez CF, Encinas M, et al. Regional cerebral blood flow in obsessive–compulsive patients with and without chronic tic disorder. A SPECT study. European Archives of Psychiatry and Clinical Neuroscience. 1999;249:156–161
  15. Deicken RF, Zhou L, Schuff N, Weiner MW. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophrenia Research. 1997;27:65–71
  16. Ebert D, Speck O, Konig A, Berger M, Hennig J, Hohagen F. 1H-magnetic resonance spectroscopy in obsessive–compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Research: Neuroimaging. 1997;74:173–176
  17. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive–compulsive disorder. Journal of Clinical Psychopharmacology. 2001;21:488–492
  18. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant obsessive–compulsive disorder. Journal of Clinical Psychiatry. 1993;54:16–26
  19. Hollander E, Prohovnik I, Stein DJ. Increased cerebral blood flow during m-CPP exacerbation of obsessive–compulsive disorder. Journal of Neuropsychiatry and Clinical Neurosciences. 1995;7:485–490
  20. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. Refractory obsessive–compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry. 2002;63:20–29
  21. Lucey JV, Costa DC, Blanes T, Busatto GF, Pilowsky LS, Takei N, et al. Regional cerebral blood flow in obsessive–compulsive patients at rest: differential correlates with obsessive–compulsive and anxious-avoidant dimensions. British Journal of Psychiatry. 1995;167:629–634
  22. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, et al. Neuroleptic addition in fluvoxamine-refractory obsessive–compulsive disorder. American Journal of Psychiatry. 1990;147:652–654
  23. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH. The efficacy of fluvoxamine in obsessive–compulsive disorder: effects of comorbid chronic tic disorder. Journal of Clinical Psychopharmacology. 1993;13:354–358
  24. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive–compulsive disorder. Archives of General Psychiatry. 1994;51:302–308
  25. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive–compulsive disorder. Archives of General Psychiatry. 2000;57:794–801
  26. McKay D, Abramowitz JS, Calamari JE, Kyrios M, Radomsky A, Sookman D, et al. A critical evaluation of obsessive–compulsive disorder subtypes: symptoms versus mechanisms. Clinical Psychology Review. 2004;24:283–313
  27. Mundo E, Bareggi SR, Pirola R, Bellodi L. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?. Biological Psychiatry. 1999;45:290–294
  28. Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai M, Takeda H, et al. Proton magnetic resonance spectroscopy of lenticular nuclei in obsessive–compulsive disorder. Psychiatry Research: Neuroimaging. 1999;92:83–91
  29. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine. 1993;30:672
  30. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, et al. Regional cerebral blood flow measured during symptom provocation in obsessive–compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Archives of General Psychiatry. 1994;51:62–70
  31. Ravi Kishore V, Samar R, Janardhan Reddy YC, Chandrasekhar CR, Thennarasu K. Clinical characteristics and treatment response in poor and good insight obsessive–compulsive disorder. European Psychiatry. 2004;19:202–208
  32. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive–compulsive disorder. Journal of Clinical Psychiatry. 1995;56:368–373
  33. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive–compulsive disorder patients taking paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry. 2000;39:1096–1103
  34. Rosenberg DR, Mirza Y, Smith DH, Russell A, Tang J, Smith JM, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. Journal of the American Academy of Child and Adolescent Psychiatry. 2004;43:1146–1153
  35. Rubin Y, LaPlaca MC, Smith DH, Thibault LE, Lenkinski RE. The effect of N-acetyl-aspartate on the intercellular calcium concentration in NTera2-neurons. Neuroscience Letters. 1995;198:209–212
  36. Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive–compulsive disorder. Neuropsychopharmacology. 1999;21:683–693
  37. Saxena S, Bota RG, Brody AL. Brain-behavior relationships in obsessive–compulsive disorder. Seminars in Clinical Neuropsychiatry. 2001;6:82–101
  38. Schwartz JM, Stoessel PW, Baxter LR, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive–compulsive disorder. Archives of General Psychiatry. 1996;53:109–113
  39. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S. Predictors of course in obsessive compulsive disorder. Psychiatry Research. 1999;89:229–238
  40. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, et al. Cerebral glucose metabolism in childhood onset obsessive–compulsive disorder. Archives of General Psychiatry. 1989;46:518–523
  41. Wiedermann D, Schuff N, Matson GB, Soher BJ, Du AT, Maudsley AA, et al. Short echo time multislice proton magnetic resonance spectroscopic imaging in human brain: metabolite distributions and reliability. Magnetic Resonance Imaging. 2001;19:1073–1080

PII: S0925-4927(06)00041-2

doi: 10.1016/j.pscychresns.2006.02.003

Psychiatry Research: Neuroimaging
Volume 154, Issue 1 , Pages 85-92 , 15 January 2007

Article Tools

* Image Usage & Resolution